Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859535 | 0.77 | HRH4 (0.46) | MEN1KMT2AHRH4MAPK1TLR9 | |
| SCHEMBL23010839 | 0.77 | TLR9 (0.47) | HTR2CHRH4TLR9TLR8TLR7 | |
| SCHEMBL17540810 | 0.76 | METAP2 (0.41) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13334409 | 0.75 | KIF11 (0.40) | HRH4 | |
| SCHEMBL29688552 | 0.74 | MAOB (0.49) | HTR2CHRH4 | |
| SCHEMBL1237690 | 0.74 | MAOB (0.49) | HTR2CHRH4 | |
| SCHEMBL13256564 | 0.74 | HTR2C (0.49) | HTR2CMEN1POLBKMT2AMAPK1 | |
| SCHEMBL8528320 | 0.74 | NPY5R (0.45) | MEN1KMT2AHRH4 | |
| Hydrochloric Acid SCHEMBL15310348 | 0.73 | HTR2C (0.50) | HTR2CMEN1POLBKMT2AMAPK1 | |
| SCHEMBL12058890 | 0.72 | MAPT (0.53) | MEN1POLBKMT2AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889674-B2 | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2404902-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | Shionogi&Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | HTR2C 267/4885MEN1 3246/4885POLB 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.